A clinical evaluation of ICRF 159 as a radiosensitising agent.
D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D003037:Cobalt Radioisotopes; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011867:Radioisotope Teletherapy; D011929:Razoxane / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
D003037:Cobalt Radioisotopes; D010879:Piperazines; D011838:Radiation-Sensitizing Agents; D011929:Razoxane